HTG MOLECULAR DIAGNOSTICS (HTGM)
US40434H3021 - Common Stock
We assign a fundamental rating of 1 out of 10 to HTGM. HTGM was compared to 40 industry peers in the Health Care Technology industry. HTGM may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, HTGM is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
HTGM had negative earnings in the past year.
In the past year HTGM has reported a negative cash flow from operations.
In the past 5 years HTGM always reported negative net income.
In the past 5 years HTGM always reported negative operating cash flow.
1.2 Ratios
The profitability ratios for HTGM are negative, so there is not much use analyzing them.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 21.69%, HTGM is doing worse than 79.55% of the companies in the same industry.
In the last couple of years the Gross Margin of HTGM has declined.
HTGM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 21.69% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-19.29%
GM growth 5Y-15.73%
2. Health
2.1 Basic Checks
HTGM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, HTGM has more shares outstanding
Compared to 5 years ago, HTGM has more shares outstanding
The debt/assets ratio for HTGM has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -35.30, we must say that HTGM is in the distress zone and has some risk of bankruptcy.
HTGM has a worse Altman-Z score (-35.30) than 90.91% of its industry peers.
A Debt/Equity ratio of 7.10 is on the high side and indicates that HTGM has dependencies on debt financing.
HTGM has a Debt to Equity ratio of 7.10. This is in the lower half of the industry: HTGM underperforms 75.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 7.1 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -35.3 |
ROIC/WACCN/A
WACC4.37%
2.3 Liquidity
A Current Ratio of 1.40 indicates that HTGM should not have too much problems paying its short term obligations.
HTGM has a worse Current ratio (1.40) than 61.36% of its industry peers.
HTGM has a Quick Ratio of 1.30. This is a normal value and indicates that HTGM is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of HTGM (1.30) is worse than 61.36% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.4 | ||
| Quick Ratio | 1.3 |
3. Growth
3.1 Past
HTGM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.99%, which is quite impressive.
The Revenue for HTGM has decreased by -28.21% in the past year. This is quite bad
HTGM shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -15.48% yearly.
EPS 1Y (TTM)44.99%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q76.54%
Revenue 1Y (TTM)-28.21%
Revenue growth 3Y-30.79%
Revenue growth 5Y-15.48%
Revenue growth Q2Q-12.83%
3.2 Future
HTGM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 39.92% yearly.
HTGM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 53.55% yearly.
EPS Next Y81.55%
EPS Next 2Y39.92%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year0.6%
Revenue Next 2Y53.55%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
HTGM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year HTGM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as HTGM's earnings are expected to grow with 39.92% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.92%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for HTGM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
HTG MOLECULAR DIAGNOSTICS
NASDAQ:HTGM (6/14/2023, 7:00:02 PM)
After market: 0.4815 +0 (+0.31%)0.48
-0.12 (-20%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.06M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 21.69% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.57
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 7.1 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.4 | ||
| Quick Ratio | 1.3 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)44.99%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y81.55%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-28.21%
Revenue growth 3Y-30.79%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y